Patent ID: 8748441
Filing Date: 2014-06-10
Classification: A61K,A61P

Abstract:
1. A method of treating a disorder selected from the group consisting of Parkinson's disease and Alzheimer's disease in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of Formula (I): in which A represents an aryl group; R a hydrogen atom, —C(O)R in which R is a hydrogen atom, a (C an optionally substituted (C R a hydrogen atom, a halogen atom, a cyano group, a nitro group, a (C R a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, an —SCF a nitro group, an oxo group, a (C a —C(O)NRbRc group, with Rb and Rc as defined below, a —C(O)ORc group or an —O—C(O)ORc group, with Rc as defined below, a (C an —O-cycloalkyl group, an —O-aryl group or an —O-heterocycloalkyl group, each optionally substituted by and —NH—CO—NH-aryl group, an —NH—CO—NH-heteroaryl group or an —NH—CO—NH—(C an —N—(C Rb represents: a hydrogen atom, a (C a (C a (C a (C an aryl group optionally substituted by one or more halogen atom(s); Rc represents a hydrogen atom or a (C or then Rb and Rc form, together with the nitrogen atom to which they are attached, a polycyclic heteroaryl group or a heterocycloalkyl group; m and n represent, independently of one another, the value 0, 1 or 2, it being understood that m+n≦3; p and p′ represent, independently of one another, the value 1, 2 or 3, it being understood that, when p is greater than or equal to 2, then the R q represents the value 0 or 2, it being understood that, when q=0, then the nitrogenous heterocyclic group attached to the nitrogen situated in the 1 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system is no longer bridged and is of the type: with R r represents the value 0 or 1; in the form of the base or of an addition salt with an acid.